Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data

被引:169
作者
del Amo, Eva M. [1 ,2 ]
Urtti, Arto [1 ,2 ]
机构
[1] Univ Eastern Finland, Sch Pharm, Kuopio 70211, Finland
[2] Univ Helsinki, Fac Pharm, Ctr Drug Res, Div Pharmaceut Biosci, FIN-00014 Helsinki, Finland
基金
芬兰科学院;
关键词
Ocular pharmacokinetics; Drug delivery; Intravitreal; Animal model; Rabbit; ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; INTRAOCULAR PHARMACOKINETICS; BLOOD-FLOW; CYTOMEGALOVIRUS RETINITIS; MACULAR DEGENERATION; VITREOUS LEVELS; DRUG; BEVACIZUMAB; CLEARANCE;
D O I
10.1016/j.exer.2015.05.003
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Intravitreal administration is the method of choice in drug delivery to the retina and/or choroid. Rabbit is the most commonly used animal species in intravitreal pharmacokinetics, but it has been criticized as being a poor model of human eye. The critique is based on some anatomical differences, properties of the vitreous humor, and observed differences in drug concentrations in the anterior chamber after intravitreal injections. We have systematically analyzed all published information on intravitreal pharmacokinetics in the rabbit and human eye. The analysis revealed major problems in the design of the pharmacokinetic studies. In this review we provide advice for study design. Overall, the pharmacokinetic parameters (clearance, volume of distribution, half-life) in the human and rabbit eye have good correlation and comparable absolute values. Therefore, reliable rabbit-to-man translation of intravitreal pharmacokinetics should be feasible. The relevant anatomical and physiological parameters in rabbit and man show only small differences. Furthermore, the claimed discrepancy between drug concentrations in the human and rabbit aqueous humor is not supported by the data analysis. Based on the available and properly conducted pharmacokinetic studies, the differences in the vitreous structure in rabbits and human patients do not lead to significant pharmacokinetic differences. This review is the first step towards inter-species translation of intravitreal pharmacokinetics. More information is still needed to dissect the roles of drug delivery systems, disease states, age and ocular manipulation on the intravitreal pharmacokinetics in rabbit and man. Anyway, the published data and the derived pharmacokinetic parameters indicate that the rabbit is a useful animal model in intravitreal pharmacokinetics. (C) 2015 The Authors. Published by Elsevier Ltd.
引用
收藏
页码:111 / 124
页数:14
相关论文
共 102 条
  • [1] Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes
    Ahn, Jeeyun
    Kim, Hyuncheol
    Woo, Se Joon
    Park, Ji Hyun
    Park, Sunyoung
    Hwang, Duck Jin
    Park, Kyu Hyung
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (07) : 612 - 618
  • [2] Intraocular Pharmacokinetics of Ranibizumab in Vitrectomized Versus Nonvitrectomized Eyes
    Ahn, Seong Joon
    Ahn, Jeeyun
    Park, Sunyoung
    Kim, Hyuncheol
    Hwang, Duck Jin
    Park, Ji Hyun
    Park, Ji Yeon
    Chung, Jae Yong
    Park, Kyu Hyung
    Woo, Se Joon
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (01) : 567 - 573
  • [3] OCULAR AND OPTIC-NERVE BLOOD-FLOW AT NORMAL AND INCREASED INTRAOCULAR PRESSURES IN MONKEYS (MACACA-IRUS) - STUDY WITH RADIOACTIVELY LABELED MICROSPHERES INCLUDING FLOW DETERMINATIONS IN BRAIN AND SOME SOME OTHER TISSUES
    ALM, A
    BILL, A
    [J]. EXPERIMENTAL EYE RESEARCH, 1973, 15 (01) : 15 - 29
  • [4] Disposition of short-chain aliphatic alcohols in rabbit vitreous by ocular microdialysis
    Atluri, H
    Mitra, AK
    [J]. EXPERIMENTAL EYE RESEARCH, 2003, 76 (03) : 315 - 320
  • [5] Pharmacokinetics of intravitreal bevackumab (avastin)
    Bakri, Sophie J.
    Snyder, Melissa R.
    Reid, Joel M.
    Pulido, Jose S.
    Singh, Ravinder J.
    [J]. OPHTHALMOLOGY, 2007, 114 (05) : 855 - 859
  • [7] Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: A one-year prospective study
    Bashshur, Ziad F.
    Haddad, Zeina A.
    Schakal, Alexandre
    Jaafar, Rola F.
    Saab, Marc
    Noureddin, Baha' N.
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (02) : 249 - 256
  • [8] Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients
    Beer, Paul M.
    Wong, Susan J.
    Hammad, Amjad M.
    Falk, Naomi S.
    O'Malley, Martin R.
    Khan, Samira
    [J]. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (08): : 871 - 876
  • [9] Bejanian M, 1999, INVEST OPHTH VIS SCI, V40, pS874
  • [10] Brubaker R F, 1982, Trans Am Ophthalmol Soc, V80, P391